Genetic screening in new onset inflammatory bowel disease during anti-interleukin 17 therapy: unmet needs and call for action

Expert Opin Biol Ther. 2021 Dec;21(12):1543-1546. doi: 10.1080/14712598.2021.1974395. Epub 2021 Aug 30.

Authors

Carlo Alberto Maronese^{1

2}, Enrico Zelin³, Chiara Moltrasio^{1

4}, Giovanni Genovese^{1

2}, Angelo Valerio Marzano^{1

2}

Affiliations

¹ Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
² Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
³ Dermatology Clinic, Maggiore Hospital, University of Trieste, Trieste, Italy.
⁴ Department of Medical Surgical and Health Sciences, University of Trieste, Trieste, Italy.

PMID: 34448662
DOI: 10.1080/14712598.2021.1974395

No abstract available

Keywords: GWAS; Genetic; IBD; IL-17; psoriasis; risk prediction; screening.

Publication types

Editorial

MeSH terms

Genetic Testing
Humans
Inflammatory Bowel Diseases* / drug therapy
Inflammatory Bowel Diseases* / genetics
Psoriasis*